Main Menu

PARSPORT

PARSPORT is a phase III multi-centre randomised controlled trial of parotid sparing IMRT in patients with head and neck cancer.

Disease site: Head and neck

Treatment modality: Radiotherapy

Status: In active follow-up 

Trial details

The PARSPORT trial is designed to demonstrate a difference in the proportion of patients suffering xerostomia (dry mouth) of grade 2 or more, 1 year after treatment, in head and neck cancer patients treated with parotid-sparing intensity modulated radiotherapy or conventional radiotherapy.

94 patients were recruited from January 2003 to December 2007 from 6 UK centres.

The work is supported by the NCRI CTrad Group and the NCRI Head and Neck Cancer Studies Group.

Chief Investigator: Dr Chris Nutting, The Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Dr Emma Hall

Trial management contact: Mark Sydenham - Trial Manager, [email protected]  

ISRCTN: 48243537

Sponsor: The Royal Marsden NHS Foundation Trust

Funding: Cancer Research UK (CRUK/03/005)

Further information

Further information on the PARSPORT trial may be found on the following sites:

Monthly accrual figures are available from the UKCRN Portfolio

Patient friendly information on the PARSPORT trial at CancerHelp UK

Publications and presentations

Buettner F, Miah AB, Gulliford SL, et al. Novel approaches to improve the therapeutic index of head and neck radiotherapy: An analysis of data from the PARSPORT randomised phase III trial. Radiother. Oncol. 2012;103(1):82-7

Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lanc. Oncol. 2011;12(2):127-36

Nutting C, Harrington K, Rogers S, Sydenham M, A'Hern R, Hall E. Results of a Phase III Multi-centre Randomised Controlled Trial of Intensity Modulated (IMRT) vs Conventional Radiotherapy (RT) in Head and Neck Cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). Clin. Oncol. 2010;22(10):899

Nutting C, J M, Sydenham M, et al. Results of a phase III multi-centre randomised controlled trial of intensity modulated (IMRT) vs conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03 005). Radiother. Oncol. 2010;96:S186 #495

Clark CH, Miles EA, Urbano MT, et al. Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and
parotid-sparing IMRT for locally advanced head and neck cancer
. Br. J. Radiol. 2009;82(979):585-94

Nutting C, A'Hern R, Rogers MS, et al. First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). J. Clin. Oncol. 2009;27(18S):LBA6006

Nutting CM, Rogers S, Sydenham M, et al. First results of a phase III multi-centre randomised controlled trial of Intensity Modulated (IMRT) vs conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN 48243537; CRUK/03/005). Eur J Cancer Supplements 2009;7(3):8

Nutting C, A'Hern R, Rogers MS, Sydenham M, Adab F, Harrington K, Jefferies S, Scrase C, Yap BK, Hall E, on behalf of the PARSPORT Trial Management Group,Results of a phase III multi-centre randomised controlled trial of intensity modulated (IMRT) vs conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). NCRI National Cancer Conference; 2009; Birmingham.

Clark CH, Miles EA, Urbano TG, Bhide S, Bidmead M, Nutting CM. Quality Assurance for an IMRT Trial: Pre-trial Exercises for PARSPORT. Clin Oncol (R.Coll.Radiol.) 2007;19(Suppl 3):#S6

Guerrero Urbano MT, Clark CH, Kong C, et al. Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines. Clin. Oncol. (R. Coll. Radiol). 2007;19(8):604-13

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.